Calcium Gluceptate

Identification

Name
Calcium Gluceptate
Accession Number
DB00326  (APRD00841)
Type
Small Molecule
Groups
Approved
Description

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly.

Structure
Thumb
Synonyms
  • Calcii Glucoheptonas
  • Calcii glugoheptonas
  • Calcium (2XI)-D-gluco-heptonate
  • Calcium bis[(2XI)-D-glycero-D-gulo-heptonate]
  • Calcium bis[(2XI)-D-glycero-D-ido-heptonate]
  • Calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]
  • Calcium Gluceptate
  • Calcium glucoheptonat
  • Calcium glucoheptonate
  • Calcium glucoheptonate (1:2)
  • Glucoheptonate de calcium
  • Glucoheptonato calcico
  • Trimethylene chlorobromide
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Liq AlsiLiquid125 mgOralAlsi Cie Ltee1980-12-312003-05-21Canada
Sirop De Calcium 625mg/5mlSyrup625 mgOralTherapex Division De E Z Em Canada Inc1980-12-311997-07-22Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralKsl Pharmaceuticals1994-12-311996-09-09Canada
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralShoppers Drug Mart Inc.1981-12-311997-08-15Canada
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralVita Health Products Inc1980-12-312002-07-31Canada
Liquid CalciumCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1998-08-122000-07-06Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GlucoheptonateCalcium Gluceptate (50 mg/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-05-23Not applicableUs
Categories
UNII
L11651398J
CAS number
29039-00-7
Weight
Average: 490.425
Monoisotopic: 490.084675939
Chemical Formula
C14H26CaO16
InChI Key
FATUQANACHZLRT-KMRXSBRUSA-L
InChI
InChI=1S/2C7H14O8.Ca/c2*8-1-2(9)3(10)4(11)5(12)6(13)7(14)15;/h2*2-6,8-13H,1H2,(H,14,15);/q;;+2/p-2/t2*2-,3-,4+,5-,6?;/m11./s1
IUPAC Name
calcium bis((3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate)
SMILES
[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O

Pharmacology

Indication

For treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin D deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, in the treatment of intestinal malabsorption, and to replenish electrolytes.

Pharmacodynamics

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly. The bones serve as a storage site for the body's calcium. They are continuously giving up calcium to the bloodstream and then replacing it as the body's need for calcium changes from day to day. When there is not enough calcium in the blood to be used by the heart and other organs, your body will take the needed calcium from the bones. When you eat foods rich in calcium, the calcium will be restored to the bones and the balance between your blood and bones will be maintained.

Mechanism of action

Calcium gluceptate replenishes the deminished levels of calcium in the body, returning them to normal levels.

Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include confusion, drowsiness (severe), high blood pressure, increased sensitivity of eyes or skin to light, irregular, fast, or slow heartbeat, and unusually large amount of urine or increased frequency of urination.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateCalcium Gluceptate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Calcium Gluceptate.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Calcium Gluceptate.
AcetyldigitoxinCalcium Gluceptate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AcetyldigoxinCalcium Gluceptate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium Gluceptate.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Gluceptate.
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Alfacalcidol.
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Gluceptate.
Food Interactions
Not Available

References

General References
  1. Drop LJ, Cullen DJ: Comparative effects of calcium chloride and calcium gluceptate. Br J Anaesth. 1980 May;52(5):501-5. [PubMed:7387803]
External Links
Human Metabolome Database
HMDB0014471
KEGG Drug
D00934
PubChem Compound
62859
PubChem Substance
46507233
ChemSpider
56591
ChEBI
3314
ChEMBL
CHEMBL1237066
PharmGKB
PA164746233
ATC Codes
A12AA10 — Calcium glucoheptonate
MSDS
Download (68.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abraxis pharmaceutical products
  • Eli lilly and co
Packagers
  • Draxis Specialty Pharmaceuticals Inc.
  • Medi-Physics Inc.
  • Spectrum Pharmaceuticals
Dosage forms
FormRouteStrength
LiquidOral125 mg
LiquidOral
Injection, powder, lyophilized, for solutionIntravenous50 mg/1
SyrupOral625 mg
Prices
Unit descriptionCostUnit
Calcium gluceptate powder12.69USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility39.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-4ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)3.38ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.51 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity55.07 m3·mol-1ChemAxon
Polarizability19.35 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9575
Blood Brain Barrier+0.5646
Caco-2 permeable-0.8513
P-glycoprotein substrateNon-substrate0.6616
P-glycoprotein inhibitor INon-inhibitor0.9743
P-glycoprotein inhibitor IINon-inhibitor0.9608
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.8702
CYP450 2D6 substrateNon-substrate0.87
CYP450 3A4 substrateNon-substrate0.7334
CYP450 1A2 substrateNon-inhibitor0.8579
CYP450 2C9 inhibitorNon-inhibitor0.9163
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorNon-inhibitor0.9106
CYP450 3A4 inhibitorNon-inhibitor0.9274
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9873
Ames testNon AMES toxic0.8429
CarcinogenicityNon-carcinogens0.838
BiodegradationReady biodegradable0.9895
Rat acute toxicity1.9804 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.938
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Heptoses / Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Secondary alcohols / Carboxylic acid salts / Polyols / Organic calcium salts / Monocarboxylic acids and derivatives
show 6 more
Substituents
Heptose monosaccharide / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Hydroxy fatty acid / Sugar acid / Fatty acyl / Fatty acid / Hydroxy acid / Monosaccharide
show 15 more
Molecular Framework
Not Available
External Descriptors
calcium salt (CHEBI:3314)

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 04:41